Locations:
SearchAdvertisement
Minimal residual disease testing shows promising results
Research indicates strong rationale for expanding trial eligibility criteria
New BMT leadership looks to clinical research and cell therapy production to overcome treatment access limitations
A New Standard of Care in Relapsed/Refractory Large B-Cell Lymphoma
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Improving safety, efficacy and access for emerging therapies
Treatment may be a lifesaving option for patients with relapsed or refractory disease
A brief look at our programs
Preliminary trial reports positive patient response
Researching and operationalizing a new therapy
Molecular markers could potentially predict major adverse side effects
Advertisement
Advertisement